

S4 Table. Data on patients with OVC providing sera for LMI profiling using triple-TOF

Sample identifier	Age (yr)	Stage	Pathology	Institution
OVC01	70	IIIA1	High-grade serous carcinoma	Korea University Guro Hospital
OVC02	52	IVA	High-grade serous carcinoma	
OVC03	45	IA	Mucinous borderline tumor	
OVC04	56	IIIB	High-grade serous carcinoma	
OVC05	51	IVB	High-grade serous carcinoma	
OVC06	51	IIIC	High-grade serous carcinoma	
OVC07	46	IIIA1	Serous adenocarcinoma	
OVC08	58	IC3	Endometrioid adenocarcinoma	
OVC09	52	IA	Hemorrhagic corpus luteum	
OVC10	66	IIB	Serous adenocarcinoma	
OVC11	54	IIA	Serous adenocarcinoma, malignant	
OVC12	46	IC3	Stromal carcinoid	
OVC13	63	IIIC	Serous carcinoma, malignant	
OVC14	56	IA	High-grade serous carcinoma	
OVC15		IVB	Reactive cellular changes associated with atrophy	
OVC16	76	IB	Mucinous carcinoma, malignant	
OVC17	37	IA	Clear cell carcinoma	
OVC18	44	IC3	Low-grade serous carcinoma	
OVC19	46	IIIC	High-grade serous carcinoma	
OVC20	40	IA	Clear cell carcinoma	
OVC21	41		Metastatic mucinous adenocarcinoma	
OVC22	54	IB	High-grade serous carcinoma, malignant	
OVC23	68	IIIC	Adenosquamous carcinoma	
OVC24	49	IIIC	Clear cell carcinoma	
OVC25	54	IIIB	Mucinous carcinoma	
OVC26	46	IIIB	High-grade serous carcinoma	
OVC27	78	IIIC	Serous carcinoma	
OVC28	63	IIIC	High-grade serous carcinoma	
OVC29	53	IVA	Metastatic adenocarcinoma	
OVC30	42	IA		

OVC, ovarian cancer; LMI, low-mass-ion; TOF, time of flight.